GSK256073 (tris)
Product Specifications
UNSPSC Description
GSK256073 tris is a potent, selective and orally active GPR109A agonist and a long-lasting and non-flushing HCA2 full agonist with a pEC50 of 7.5 (human HCA2). GSK256073 tris acutely improves glucose homeostasis via inhibition of lipolysis and has the potential for the study of type 2 diabetes mellitus (T2DM)and dyslipidemia[1][2]. GPR109A: G-protein coupled receptor 109A; HCA2: hydroxy-carboxylic acid receptor 2
Target Antigen
GPR109A
Type
Reference compound
Related Pathways
GPCR/G Protein
Field of Research
Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/gsk256073-tris.html
Smiles
O=C1NC(N(CCCCC)C2=C1NC(Cl)=N2)=O.OCC(CO)(CO)N
Molecular Weight
377.82
References & Citations
[1]Dobbins RL, et al. GSK256073, a selective agonist of G-protein coupled receptor 109A (GPR109A) reduces serum glucose in subjects with type 2 diabetes mellitus.Diabetes Obes Metab. 2013 Nov;15(11):1013-21.|[2]Sprecher D, et al. Discovery and characterization of GSK256073, a non-flushing hydroxy-carboxylic acid receptor 2 (HCA2) agonist.Eur J Pharmacol. 2015 Jun 5;756:1-7.
Shipping Conditions
Room temperature
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-119222A/GSK256073-tris-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-119222A/
Clinical Information
Phase 2
CAS Number
1228650-42-7
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
